Kura Oncology (KURA) Revenue (2025 - 2026)
Kura Oncology (KURA) reported Revenue of $18.3 million for Q1 2026, up 29.47% year-over-year from $14.1 million in Q1 2025, and up 5.36% quarter-over-quarter from $17.3 million in Q4 2025.
Kura Oncology (KURA) Revenue (2025 - 2026) Analysis & Trends
Kura Oncology (KURA) has 2 years of Revenue data on file, last reported at $18.3 million in Q1 2026.
- Revenue for Q1 2026 came in at $18.3 million, up 29.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $71.6 million (changed N/A YoY), and the FY2025 annual result was $67.5 million, up 25.24% from the prior year.
- Revenue advanced to $18.3 million in Q1 2026 per KURA's latest filing, from $17.3 million in the prior quarter.
- Over five years, Revenue peaked at $20.8 million in Q3 2025 and troughed at $14.1 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 5.21 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 306.30 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 2.99 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Kura Oncology | 883.44 Mn | 883.44 Mn | 18.00 Mn | 18.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.27 Mn |
| Dec 31, 2025 | 17.34 Mn |
| Sep 30, 2025 | 20.75 Mn |
| Jun 30, 2025 | 15.29 Mn |
| Mar 31, 2025 | 14.11 Mn |